公开(公告)号：US20240361301A1

公开(公告)日：2024-10-31

申请号：US18687654

申请日：2022-09-09

Applicant: Flagship Pioneering Innovations VI, LLC

Inventor： Morag Helen STEWART ,  Angeliki CHALKIADAKI ,  Yuge JI ,  Fabian Alexander WOLF ,  Nicholas McCartney PLUGIS ,  Poorya HOSSEINI ,  Inna LIPCHINA ,  Sophie Andrea TRITSCHLER

IPC: G01N33/50 ,  A61K45/06 ,  C12N5/071

CPC classification number: G01N33/5088 ,  A61K45/06 ,  C12N5/0679 ,  G01N33/5023 ,  C12N2503/04 ,  C12N2533/90

Abstract: The present disclosure relates, inter alia, to perturbagens and methods for directing a change in the cell state of an intestinal stem cell and/or a basal cell. It also relates to methods for increasing a quantity of goblet progenitors, goblet cells, Paneth cells, and/or enteroendocrine cells or immediate progenitors thereof and/or the ratios thereof, and methods for decreasing the function and quantity of goblet cells or immediate progenitors thereof. Further, the present disclosure relates to methods for treating diseases or disorders characterized by, at least, abnormal function, abnormal ratios and/or abnormal numbers of goblet progenitors, goblet cells, Paneth cells, and/or enteroendocrine cells, or immediate progenitors thereof.

公开(公告)号：US20240360241A1

公开(公告)日：2024-10-31

申请号：US18605139

申请日：2024-03-14

Applicant: Bionomics Inc.

Inventor： Christopher L. Reyes ,  Peter Chu ,  Kristen M. Smith ,  Lioudmila A. Campbell ,  Farbod Shojaei ,  John Thomas Norton

IPC: C07K16/30 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/7068 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

CPC classification number: C07K16/30 ,  A61K31/337 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K31/7068 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/28 ,  C07K16/2869 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Embodiments include humanized anti-LGR5 antibodies for the treatment of cancer. Some embodiments include antibodies which may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Some embodiments include heavy and light chain polypeptide sequences for the binding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.

公开(公告)号：US20240360235A1

公开(公告)日：2024-10-31

申请号：US18628224

申请日：2024-04-05

Applicant: Bristol-Myers Squibb Company ,  Celldex Therapeutics, Inc.

Inventor： Vladimir CORIC ,  Tibor KELER ,  Thomas DAVIS

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/30

CPC classification number: C07K16/2878 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/0011 ,  A61K39/001129 ,  A61K39/00115 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76

Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.

公开(公告)号：US20240360229A1

公开(公告)日：2024-10-31

申请号：US18416525

申请日：2024-01-18

Applicant: Genentech, Inc.

Inventor： Christoph SPIESS ,  Baomei WANG ,  Ambrose Jon WILLIAMS ,  Cecilia Pui Chi CHIU ,  Michael Andrew DILLON ,  Teemu Tapani JUNTTILA ,  James Thomas KOERBER

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2809 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73

Abstract: The present invention provides anti-C-C motif chemokine receptor 8 (CCR8) antigen-binding molecules (e.g., bispecific antigen-binding molecules) and compositions thereof. The invention also features polynucleotides, vectors, host cells, methods of production, pharmaceutical compositions, methods of treating a disease or disorder, such as cancer, methods of depleting regulatory T cells, related uses and compositions for use, and kits for use with the one or more methods.

公开(公告)号：US20240360212A1

公开(公告)日：2024-10-31

申请号：US18766765

申请日：2024-07-09

Applicant: Janssen Biotech, Inc.

Inventor： Bruce Randazzo ,  Yasmine Wasfi

IPC: C07K16/24 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P17/06

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61P17/06 ,  C07K16/241 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565

Abstract: A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a safe and effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment.

公开(公告)号：US20240360155A1

公开(公告)日：2024-10-31

申请号：US18584520

申请日：2024-02-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brian C. SHOOK ,  In Jong KIM ,  Thomas P. BLAISDELL ,  Jianming YU ,  Joseph D. PANARESE ,  Yat Sun OR

IPC: C07D513/04 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08

CPC classification number: C07D513/04 ,  A61K31/5513 ,  A61K31/56 ,  A61K31/58 ,  A61K45/06 ,  C07D243/16 ,  C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/08 ,  C07D491/048 ,  C07D495/04 ,  C07D498/08

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:




which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20240360152A1

公开(公告)日：2024-10-31

申请号：US18659374

申请日：2024-05-09

Applicant: Arvinas Operations, Inc.

Inventor： Erika Marina Vieira Araujo ,  Michael Berlin ,  Hanqing Dong ,  Steven M. Sparks ,  Jing Wang ,  Wei Zhang

IPC: C07D498/10 ,  A61K45/06 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10

CPC classification number: C07D498/10 ,  A61K45/06 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10

Abstract: Bifunctional compounds, which find utility as modulators of leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the hetero-bifunctional compounds of the present disclosure contain on one end a moiety that binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds LRRK2, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The hetero-bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aberrant regulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

公开(公告)号：US20240360138A1

公开(公告)日：2024-10-31

申请号：US18537700

申请日：2023-12-12

Applicant: Virginia Commonwealth University ,  Sanford Burnham Prebys Medical Discovery Institute

Inventor： Paul B. Fisher ,  Maurizio Pellecchia ,  Swadesh K. Das ,  Timothy P. Kegelman ,  Bainan Wu ,  Surya K. De ,  Jun Wei ,  Mitchell E. Menezes ,  Luni Emdad

IPC: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  C07D495/14

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K45/06 ,  A61P35/04 ,  C07D495/14

Abstract: Provided herein are, inter alia, compositions that bind to a PDZI domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.

公开(公告)号：US20240360108A1

公开(公告)日：2024-10-31

申请号：US18581307

申请日：2024-02-19

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ermira PAZOLLI ,  Silvia BUONAMICI ,  Thiwanka SAMARAKOON ,  Sudeep PRAJAPATI ,  Nathan FISHKIN ,  James PALACINO ,  Michael SEILER ,  Ping ZHU ,  Andrew COOK ,  Peter SMITH ,  Xiang LIU ,  Shelby ELLERY ,  Dominic REYNOLDS ,  Lihua YU ,  Zhenhua WU ,  Shouyong PENG ,  Nicholas CALANDRA ,  Megan SHEEHAN ,  Yonghong XIAO

IPC: C07D405/12 ,  A61K9/127 ,  A61K9/51 ,  A61K31/365 ,  A61K31/496 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K47/60 ,  A61K47/68 ,  A61P35/00 ,  C07D313/00 ,  C07D405/06 ,  C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/574

CPC classification number: C07D405/12 ,  A61K9/127 ,  A61K9/51 ,  A61K31/365 ,  A61K31/496 ,  A61K39/0011 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6857 ,  A61K47/6869 ,  A61K47/6871 ,  A61K47/6889 ,  A61P35/00 ,  C07D313/00 ,  C07D405/06 ,  C07K16/24 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2896 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/32 ,  C07K16/40 ,  C12Q1/6886 ,  G01N33/5011 ,  G01N33/574 ,  A61K2039/505 ,  A61K2039/53 ,  A61K2039/545 ,  C07K2317/565 ,  C07K2317/76 ,  C12Q2600/106 ,  G01N2500/10

Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

公开(公告)号：US20240358719A1

公开(公告)日：2024-10-31

申请号：US18553474

申请日：2021-03-31

Applicant: The Board of Trustees of the Leland Stanford Junior University ,  Trustees of Boston University

Inventor： Liang Liang ,  Michael P. Snyder ,  Cristina M. Alvira ,  David N. Cornfield ,  Lihua Ying ,  John K. Snyder

IPC: A61K31/58 ,  A61K31/522 ,  A61K31/573 ,  A61K31/704 ,  A61K45/06 ,  A61P15/06

CPC classification number: A61K31/58 ,  A61K31/522 ,  A61K31/573 ,  A61K31/704 ,  A61K45/06 ,  A61P15/06

Abstract: Methods and formulations of treatment for menstrual complications, gestational complications, and to prolong gestation are described. Treatments include administration of a compound related to regulation of gestational progress or uterine contractions.